We recently reported our discovery of small molecule b b-1,6-glucan inhibitor named D75-4590 and the antiCandida activity of its derivatives D11-2040 and D21-6076. In this study, we further evaluated the antifungal profile of D11-2040. It alone strongly inhibited the vegetative growth and/or hyphal development of various Candida species, but no significant activity was observed against Cryptococcus neoformans or any of the filamentous fungi tested. Synergism was detected for C. albicans in the interaction of D11-2040 and caspofungin by the chequerboard method and in that of D11-2040 and fluconazole by the time-kill method. Slight but positive interactions were observed in several combinations for C. neoformans and Aspergillus fumigatus as well. These results suggested that b b-1,6-glucan inhibitors have promising potential as single drugs as well as concomitants.
Fungi are responsible for various types of diseases, from non-life threatening mucocutaneous infections to serious systemic infections. Despite recent progress in the management of these infections, they still pose a number of challenges in clinical settings. [1] [2] [3] [4] The unacceptably high mortality rate of proven invasive fungal infections is one of the most critical issues. 4) Although the recent introduction of new azoles and echinocandins has improved the outcome to some extent, their limited success rate has led to a variety of combination antifungal therapies. These could be beneficial options for at least several types of difficult-to-treat infections. 5) However, in most cases the limited diversity of the mechanisms of action among the currently available drugs and the controversial results of the studies of combination therapies have failed to offer sufficient evidence to make them major treatments. 6, 7) On the other end of the scale, although mucosal fungal infections are generally not fatal, the emergence of resistant species and strains as well as frequent recurrences, especially in the case of vaginal candidiasis, has become problematic. 3, 8) Oral administration of fluconazole is frequently prescribed for recurrent vulvovaginal candidiasis mainly because of its good penetration in the vaginal tissue and high tolerance. However, its teratogenecity, limited spectrum and fungistatic nature restrict the cases and prolong the duration of the treatment.
We recently reported our discovery of a small molecule b-1,6-glucan inhibitor named D75-4590. 9) It is expected to be promising lead for novel antifungal drugs because b-1,6-glucan is thought to be a fungi-specific and an essential component. 10) Besides, Kre6p, which is the predicted primary target of D75-4590, has been found in various fungi, including Candida species, Cryptococcus neoformans and Aspergillus species, but not in humans. 9, 11, 12) However, the essentiality of Kre6p and its homologue(s) has not been suggested in most species. Since no other b-1,6-glucan inhibitor has been reported so far, studies on D75-4590 and its derivatives would be valuable in obtaining a better understanding of the antifungal profile of b-1,6-glucan inhibitors and how beneficial they could be.
In the course of our effort to search for derivatives suitable for antifungal drugs, we found several derivatives, including D11-2040 and D21-6076, which have more suitable profiles for further characterization of b-1,6-glucan inhibitors. In our previous study, we focused on their in vivo efficacy and their effects on the invasion process of C. albicans. 13) In this study, to estimate the possible utility of b-1,6-glucan inhibitors in clinical settings, we evaluated the in vitro activities of D11-2040 against various fungi and its interaction with other antifungal agents.
MATERIALS AND METHODS

Strain and Media
The fungi used in this study are listed in Table 1 . They were purchased from the American Type Culture Collection (ATCC; Rockville, MD, U.S.A.), the Institute for Fermentation Osaka (IFO, Osaka, Japan), Riken Bioresource Center (JCM, Tokyo, Japan) or the Institute of Molecular and Cellular Biosciences, University of Tokyo (IAM, Tokyo, Japan). The media used in this study were Sabouraud dextrose agar (SDA; Difco, Detroit, MO, U.S.A.), RPMI (RPMI 1640 culture medium (Sigma, St. Louis, MO, U.S.A.) buffered with 0.165 M MOPS (3-[N-morpholino]-propanesulphonic acid)ϩ2% glucose, pH 7.0), 14) hyphal forming medium 7 (HFM-7; 5 mg/ml glucose, 0.26 mg/ml Na 2 HPO 4 · 12H 2 O, 0.66 mg/ml KH 2 PO 4 , 0.08 mg/ml MgSO 4 · 7H 2 O, 0.33 mg/ml NH 4 Cl, 16 mg/ml biotin, 4% fetal bovine serum), 13) RP medium (RPMI1640, 2.5% fetal calf serum, 20 mM N-(2-hydroxyethyl)piperazine-NЈ-2-ethanesulfonic acid (HEPES), 16 mM sodium hydrogen carbonate (pH 7.0)) Lee's medium and Spider medium. 15, 16) Chemicals D11-2040 (2-ethyl-(2-NЈ,NЈ-diethylaminoethyl)amino-3-methylpyrido[1,2-a ]benzimidazole-4-carbonitrile) was synthesized in our laboratories. Its structure is shown in Fig. 1 . Amphotericin B (AMB), fluconazole (FLC) and 5-flucytosine (5FC) were purchased from Sigma. Itraconazole (ITC) and caspofungin (CAS) were purchased from Janssen (Tokyo, Japan) and Merk (Whitehouse Station, NJ, U.S.A.), respectively. The drugs were dissolved in dimethyl sulphoxide (DMSO) and were used for biological testing at final concentrations of DMSO less than 1%.
Antifungal and Antibacterial Susceptibility Testing
The minimum inhibitory concentration (MIC) for each fungal strain was measured by the microdilution method described by the Clinical and Laboratory Standards Institute (CLSI), with slight modifications as follows. 14) To measure a reproducible and accurate MIC, an oxidation-reduction indicator, alamar blue (Biosource, Camarillo, CA, U.S.A.) was added to the medium according to the manufacturerer's instructions. 17) Cell suspensions were prepared in sterile saline and were counted under microscopy using a hemocytometer. They were added to the medium to give final inoculum densities ranging from 1ϫ10 3 to 3ϫ10 3 cells/ml. The test plates were statically incubated and were measured at OD 570 with a Wallac 1420 ARVOsx (Wallac, Tokyo, Japan) multi-label counter just before the drug-free control well turned pink. The MIC-0 (the lowest drug concentration producing an optically clear well) or the MIC-2 (the lowest drug concentration producing a prominent reduction in turbidity) was used as an endpoint for AMB or for FLC, ITC, 5FC and D11-2040. For CAS, MIC-2 was used in filamentous fungi and MIC-0 was used in yeast. The MIC-2 is defined as a 50% reduction in absorbance at 570 nm compared with the drug-free control. Since the activities of D11-2040 alone against several Candida species were partial, which makes its MICs fluctuate, the tests were repeated at least five times on different days. MICs for bacterial strains were determined by CLSI method.
18)
Measurement of Effect on Hyphal Growth
The effect of D11-2040 against the hyphal growth of C. albicans ATCC24433 was observed by the methods described previously. 9) Briefly, cell suspensions with or without drug were cultured in HFM-7. After static incubation at 37°C for 24 h, the cells were examined with a DMLB100 light microscope (Lica, Wetzlar, Germany). In order to quantify the extent of hyphal growth, a crystal violet (CV) staining assay was carried out by the methods reported by Wakabayashi et al. with slight modifications. 14, 19) As another way of quantification, MICs of D11-2040 were measured in Speider medium and Lee's medium, which are known to induce the hyphal growth of C. albicans. The initial cell densities were 1ϫ10 3 cells/ml and the MIC determinations were done after incubation at 37°C for 18 to 24 h. The MIC-2 was defined as a 50% reduction in the absorbance at 600 nm and was used as the endpoint. All experiments were performed in duplicates.
Combination Studies (i) Chequerboard Microdilution Studies: The interactions between D11-2040 and AMB, FLC, ITC or CAS against three strains were assessed by a chequerboard technique using MOPS-buffered RPMI plus alamar blue as a medium. 13, 14) The ranges of concentration of the established drugs were set so as to include at least 1/4 to 8ϫMIC of each drug against the strains tested. That of D11-2040 ranged from 32 to 0.032 mg/ml. MIC-0 or MIC-2 was chosen as an endpoint depending on the counterpart drug of D11-2040 used. The measurements for C. albicans, C. neoformans and A. fumigatus were done after incubation for 1, 3 and 2 d, respectively. The fractional inhibitory concentration index (FICI) was calculated for each combination and synergy was defined as an FICI of Յ0.5, and indifference was defined as FICI of Ͼ0.5 but Յ4, whereas antagonism was defined as an FIC of Ͼ4.
(ii) E-Test Studies: The interactions between D11-2040 and AMB, FLC, ITC or 5FC against C. albicans ATCC24433 were evaluated by the E-test method described by Kontoyiannis et al. 20) using MOPS-buffered RPMI agar (1.5%) plate containing 0, 1 or 5 mg/ml of D11-2040. The 0.5 McFarland inoculums of C. albicans ATCC24433 were swabbed on the entire RPMI-agar plates and E-test strips (AB Biodisk, solna, Sweden) were applied. The plates were incubated at 35°C and the MICs were read after 24 and 48 h. Plates images after incubation were acquired with a digital camera.
(iii) Time-Kill Studies: The interactions between D11-2040 and FLC against C. albicans ATCC24433 were evaluated using time-kill methods. 21, 22) Exponentially growing cells of C. albicans ATCC24433 were suspended in MOPSbuffered RPMI with or without drugs at a starting inoculum of 2ϫ10 3 CFU/ml. Samples were taken after 4, 8 and 24 h of incubation with gentle agitation at 30°C. The samples were diluted appropriately and spread on Sabouraud dextrose agar (SDA) plates. The number of viable cells in each sample was measured by counting the colonies on each plate after an 
RESULTS
In Vitro Activities of D11-2040 Alone
The antifungal activities of D11-2040 and reference agents against various yeast and filamentous fungi in the CLSI method are summarized in Table 1 . D11-2040 showed potent activities against a variety of Candida species, including azole-resistant strains, but no activity against C. neoformans, Trichosporon species and filamentous fungi except for Paecilomyces variotii. The MICs of D11-2040 against bacterial strains (Staphylococcus aureus 209P and Escherichia coli NIHJ) were Ͼ32 mg/ml. As reported, D11-2040-treated cells of C. albicans were extremely clumped, presumably due to the loss of b-1,6-glucan-anchored cell wall proteins, but they could grow slowly in MOPS-buffered RPMI.
14) The nature of D11-2040 resulted in characteristic "trailing growth phenomenon"; partial growth inhibitions with significant morphological changes visible at a wide range of drug concentrations (Fig. 2) . These effects of D11-2040 were clear in all the strains of C. tropicalis, C. parapsilosis, as well as C. albicans except for C. tropicalis ATCC200956. Since the extent of the growth defect in C. parapsilosis strains caused by D11-2040 is relatively high, "trailing growth phenomenon" did not affect its MIC values against these strains. On the other hand, although the morphological abnormality of all of the strains of C. tropicalis and C. albicans tested were observed at the concentrations less than 0.1 mg/ml, the extent of the growth inhibition was relatively low and varied among the strains, which lead to significant differences in the MIC values among these strains. Thus, although the MICs of several Candida strains were Ͼ8 mg/ml, we do not think that it simply means they are "resistant," which prompted us to further investigate these strains.
b-1,6-Glucan inhibitors including D11-2040 were shown to have an inhibitory effect on the hyphal growth of C. albicans. 9, 13) To quantify this inhibitory effect and compare its activities against various strains, a CV staining assay was performed for five strains of C. albicans (Table 2 ). IC 80 s of D11-2040 for these strains were similar and relatively low (ranging from 0.032 to 0.125 mg/ml) in spite of the large differences in the MIC values among these strains. We have also tried to measure its effects on the hyphae of C. tropicalis, but failed to measure reproducible IC 80 values because the drugfree wells were not dyed well with crystal violet, probably due to insufficient attachment of the fungal cells to the well bottom and/or a relatively small amount of hyphal growth. Therefore, the effects were assessed by measuring the MICs against C. tropicalis strains with Lee's medium and Spider medium, which is known to induce hyphal growth. Although both of the strains of C. tropicalis tested did not grow well in Lee's medium, both developed long hypha in Spider medium. D11-2040 showed low MICs against all C. tropicalis strains, as well as C. albicans strains, in either or both mediums (Table 3) . These results suggested that D11-2040 strongly inhibits the hyphal growth of C. albicans and C. tropicalis, regardless of its MIC values in the CLSI method.
In Vitro Activities of D11-2040 Combination with Other Antifungal Drugs Since D11-2040 has a novel mechanism of action on the cell wall, it is promising that D11-2040 enhances the activities of other antifungal drugs. To characterize the in vitro interaction of D11-2040 with the currently available antifungal drugs, several combination studies were conducted. First, the effects of the combination of D11-2040 and FLC, ITC, AMB or CAS against C. albicans, C. neoformans and A. fumigatus were evaluated with a conventional chequerboard microdilution method. The results for each counterpart drug alone and in combination are summarized in Table 4 . All the tests were repeated three times and the results showed the same tendencies (data not shown). By itself, D11-2040 has few (C. albicans) or no significant effects (C. neoformans and A. fumigatus). However, the MIC of the counter drug was reduced by one to two dilutions in most cases when combined with D11-2040. Among these, clear synergism was observed in C. albicans with a D11-2040-CAS combination. Although it was interpreted as "indifference," the positive interaction of the D11-2040-CAS combination for A. fumigatus and the D11-2040-ITC combination for C. neoformans were clear and reproducible. No result of the combinations was interpreted as "antagonism." To further characterize the effects of the combinations on C.
albicans, E-test-based experiments were conducted. As indicated in Table 5 , D11-2040 slightly increased the MIC of AMB and decreased those of 5FC, ITC and FLC after 24 h incubation, all of which were interpreted as "indifferent." Interestingly, drastic changes were observed after an additional 24 h of incubation. Since 5FC, ITC and FLC are fungistatic, the inhibitory zone of 5FC became smaller and countless small colonies appeared in the inhibitory zone of FLC and ITC after an additional 24 h incubation on agar plates without D11-2040 (Fig. 3a) . On the contrary, no colony was observed inside the inhibitory zones of FLC and ITC on the agar plates with 1 mg/ml D11-2040 (Fig. 3b) . Although spontaneous colonies appeared, the inhibitory zone of 5FC on the agar plates with 1 mg/ml D11-2040 was much larger than on the agar plate without any drugs (Fig. 3b) . These results indicated that D11-2040 may enhance the partial growth inhibitory effects of these drugs. These observations encouraged us to conduct a dynamic analysis of D11-2040-FLC interaction by the time-kill curve method. Positive interactions were clearly confirmed in this experiment (Fig. 4) . The inhibitory effect of D11-2040 or FLC alone was detectable but it yielded only 0.5 log 10 or 1.2 log 10 growth reductions, respectively, even at the highest concentration tested. The growth reduction of FLC was clearly augmented by the addition of D11-2040 at its sub-optimal concentration (1 mg/ml) as well as its optimal concentration (4 mg/ml) to an extent that is not achievable by FLC alone. At maximum, 2.3 log 10 growth reductions were observed by adding 0.125 mg/ml of D11-2040 at the concentration of 1 mg/ml of FLC, which was interpreted as synergism. This result strongly indicated that the disappearance of the small colonies on the E-test agar with D11-2040 was caused by the enhancement of growth reduction by D11-2040. In Vivo Efficacy of D11-2040 Combination with FLC First, we examined the protective effects of 1 d treatment with D11-2040 alone on experimental systemic infections caused C. albicans ATCC90028 and observed no significant efficacy (data not shown). Next, the efficacy of the combination treatment with D11-2040 plus FLC was tested in the same model (Fig. 5 ). The treatment with FLC alone at nonprotective dose (1 mg/kg, intravenously) resulted in prolonged survival compared with the survival of untreated controls, but all mice died by day 6. With the addition of D11-2040 (5, 10 or 20 mg/kg/dose, per os) to FLC, significant improvement in survival was found in dose dependent fashion.
DISCUSSION
Although most of C. albicans or C. tropicalis strains showed high MICs (8 mg/ml or more), D11-2040 inhibited their hyphal growth at low concentrations. As we previously reported, D21-6076, a derivative of D11-2040, exhibited in vivo efficacy against C. albicans although it only weakly reduced the growth of C. albicans in conventional media and its in vivo efficacy can be explained by its inhibitory effects on the invasion process of C. albicans, including hyphal elongation. 13) Taking this evidence into consideration, b-1,6-glucan inhibitors can be effective against C. tropicalis in vivo as well.
The inhibitory activities of D11-2040 against the hyphal growth of 6 strains of C. albicans were similar in spite of the large differences in their activities against vegetative growth (MICs in CLSI tests). Previous reports suggested the inhibitory activities of b-1,6-glucan inhibitors against hyphal growth correlated with their effects on b-1,6-glucan synthesis, 13) which means that their activities against vegetative growth do not correlated with their effects on b-1,6-glucan synthesis. Therefore, the large differences in their MICs in CLSI tests may possibly be attributed to the differences in the nature of these strains, such as the importance of b-1,6-glucan for their vegetative growth. Further evaluations are in progress.
Although KRE6 have been found in some species of Aspergillus as well as C. neoformans, D11-2040 itself shows no significant activity against these species. Henry et al. suggested that A. fumigatus does not have a b-1,6-glucan component in the cell wall and that Kre6p probably has a role in the cell wall contraction different from b-1,6-glucan synthesis. 11, 23) Siafakas et al. suggested that a GPI-anchored protein of C. neoformans is covalently attached to b-1,6-glucan like other yeasts. 24) In our study, although they were interpreted as "indifferent," D11-2040 reduced the MICs of several drugs tested for A. fumigatus or C. neoformans and such effects were reproducible. Taking these findings together, one possible explanation for the results of this study is that D11-2040 has an effect on the cell wall of these species, but it does not induce prominent growth defects because KRE6 is not essential for these species.
This study suggested that D11-2040 enhanced the activities of FLC and CAS in a different way. We speculate that The strains at starting inocula of 2ϫ10 3 CFU/ml were exposed to FLC and/or D11-2040 at the concentration indicated in each figure. The viable cells were counted at intervals using an SDA plate. Abbreviations: FLC, fluconazole. this difference may be attributed to differences in the mechanisms of their interaction. The positive interactions of D11-2040 and other drugs can be explained by two different mechanisms. One mechanism is that D11-2040 alters the permeability of the counterpart drugs into the cell. We previously showed that b-1,6-glucan inhibitor destroys the mannan layer, which seems to act as a barrier to the permeation of some antifungal drugs. 10, 13) Therefore, it is understandable that D11-2040 enhances the activities of other drugs in this way. If positive interaction is simply caused through this mechanism, such an effect is supposed to reduce the MIC value of the counterpart drug, which can be easily detected by the chequerboard method. Another possible way is that the extent of the growth reduction of the fungal cells caused by the partner drug was enhanced by the action of D11-2040. This is possible simply because D11-2040 has a different mechanism of action from those of the other drugs. Such an effect can be detected by the time-kill method but a chequerboard test will often fail to detect these effects due to its limited detectable range regarding the extent of growth defects. Thus, we suppose that D11-2040 could show synergy with other drugs through different mechanisms and that these synergisms are not always detectable by one method, but the use of other methods is necessary. From the viewpoint of our hypothesis above, the positive interaction in the time-kill study of D11-2040-FLC combination could indicate that D11-2040 enhances the growth defect caused by FLC and that in the chequerboard test of D11-2040-CAS combination could indicate that D11-2040 accelerates the permeability of CAS into the cell.
The positive interactions of D11-2040 and established antifungal drugs suggested that b-1,6-glucan inhibitors can potentially provide beneficial options in combination therapy. If such effects actually reflect in clinical setting, we think that a D11-2040-FLC combination would be excellent for the following reasons. The major drawbacks of azoles are their fungistatic mode of action and insufficient activity against C. glabrata and C. krusei. D11-2040 was shown to have a compensatory profile for these drawbacks, that is, it has potent activities against these species and enhances the growth defect caused by FLC when used in combination. On the other hand, one of the biggest advantages of azoles is that they are orally active. It seems possible to make derivatives of D11-2040 which are orally active as well because it is small molecule with a broad range of derivatization.
In conclusion, our study suggests that b-1,6-glucan inhibitors have promising potential as single drugs as well as concomitants. Although we observed positive interaction of D11-2040 and FLC in a mice model as well, further studies are needed to demonstrate in detail how their unique characteristics translate to in vivo efficacy and what kind of benefit we could offer with this class of inhibitors in clinical settings. Precise and in-depth investigations of their in vivo efficacy are underway.
